Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial

Yenny Dian Andayani, Mgs. Irsan Saleh, Aru Wisaksono Sudoyo, Zulkhair Ali, Legiran Legiran, Radiyati Umi Partan, Eddy Yuristo, Fadhyl Zuhry Lubis

Abstract


Background: Hand Foot Syndrome (HFS) is a frequent adverse effect observed in patients undergoing capecitabine chemotherapy, often leading to treatment disruptions and dose adjustments. Elevated C-Reactive Protein (hs-CRP) levels have been associated with the development of HFS. This study aimed to assess the potential of unrefined Extra Virgin Olive Oil (EVOO) supplementation in mitigating HFS and hs-CRP elevation among individuals receiving capecitabine chemotherapy. Methods: Between November 2022 and May 2023, forty-five eligible participants were enrolled in this randomized trial. Patients with advanced colorectal or breast cancer were randomly allocated into three groups: an intervention group receiving unrefined EVOO supplementation (30 mL per day) alongside capecitabine, a placebo group receiving refined extra light olive oil (ELOO) supplementation (30 mL per day) alongside capecitabine, and a control group receiving capecitabine alone. The masking of both placebo and intervention groups was ensured through identical packaging and instructions, maintaining participant and physician blindness to the assigned treatments. Randomization, achieved via computer-generated sequences, ensured even distribution among the three groups. Results: HFS incidences were notably lower in the EVOO group (13.3%) compared to the placebo (66.7%) and control (80%) groups. Instances of Grade 2 or more severe HFS were observed in 20% of placebo and 40% of control group patients. No cases of severe HFS were reported in the EVOO group. Moreover, EVOO supplementation led to a significant reduction in hs-CRP levels when contrasted with the placebo and control groups. These findings suggest that EVOO may serve as a preventive measure against HFS and exhibit anti-inflammatory effects in patients undergoing capecitabine chemotherapy. Conclusion: This study demonstrates the potential benefits of incorporating unrefined EVOO into the regimen of patients undergoing capecitabine chemotherapy. EVOO supplementation was associated with lower incidences of HFS and a reduction in hs-CRP levels, indicating its possible role in preventing HFS development and mitigating inflammation.


Keywords


Hand Foot Syndrome; C-Reactive Protein; Extra Virgin Olive Oil; Capecitabine

References


Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020;14(1):442. doi:10.4081/oncol.2020.442

Urakawa R, Tarutani M, Kubota K, Uejima E. Hand Foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy. J Cancer. 2019;10(20):4846-51. doi:10.7150/jca.31059

Nikolaou V, Syrigos K, Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 2016;15(12):1625-33. doi:10.1080/14740338.2016.1238067

Watts K, Wills C, Madi A, et al. Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. Int J Cancer. 2022;151(6):957-66. doi:10.1002/ijc.34046

Kanbayashi Y, Taguchi T, Ishikawa T, Otsuji E, Takayama K. Risk factors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study. Oncology. Published online April 19, 2023:1. doi:10.1159/000529851

Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787-94. doi:10.1016/j.jaad.2014.03.019

Jimenez-Lopez C, Carpena M, Lourenço-Lopes C, et al. Bioactive compounds and quality of extra virgin olive oil. Foods. 2020;9(8):1014. doi:10.3390/foods9081014

Pozzetti L, Ferrara F, Marotta L, et al. Extra virgin olive oil extracts of indigenous southern tuscany cultivar act as anti-inflammatory and vasorelaxant nutraceuticals. Antioxidants. 2022;11(3):437. doi:10.3390/antiox11030437

Saif MW, Elfiky AA. Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. J Support Oncol. 2007;5(7):337-343.

de Queiroz MVR, de Medeiros ACTR, Toledo SP, de Abreu Sarmenghi KD, de Vasconcellos VF. Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation. ecancermedicalscience. 2022;16:1390. doi:10.3332/ecancer.2022.1390

Segura-Carretero A, Curiel JA. Current disease-targets for oleocanthal as promising natural therapeutic agent. Int J Mol Sci. 2018;19(10):2899. doi:10.3390/ijms19102899

Murphy R. Extra-virgin olive oil has similar activity to ibuprofen. Nat Clin Pract Rheumatol. 2005;1(2):66-66. doi:10.1038/ncprheum0023

Liang J, Bonvino NP, Hung A, Karagiannis TC. In silico characterisation of olive phenolic compounds as potential cyclooxygenase modulators. Part 1. J Mol Graph Model. 2020;101:107719. doi:10.1016/j.jmgm.2020.107719

Siddique AB, Kilgore PCSR, Tajmim A, et al. Oleocanthal as a dual c-MET-COX2 inhibitor for the control of lung cancer. Nutrients. 2020;12(6). doi:10.3390/nu12061749

Costa V, Costa M, Videira RA, Andrade PB, Paiva-Martins F. Anti-inflammatory activity of olive oil polyphenols—The role of oleacein and its metabolites. Biomedicines. 2022;10(11):2990. doi:10.3390/biomedicines10112990


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.